Search Results - "Elezar, E."

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

    Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study by Jelić, Svetislav, Mitrović, Labuda, Radosavljević, Davorin, Elezar, Elizabeta, Babović, Nada, Kovčin, Vladimir, Tomašević, Zoran, Kovačević, Svetlana, Gavrilović, Dušica, Radulović, Siniša

    Published in Lung cancer (Amsterdam, Netherlands) (01-10-2001)
    “…This communication represents the definitive report of a randomized phase III study comparing cisplatin and carboplatin, in combination with vindesine and…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    45 Survival advantage for carboplatin 500 mg/mg2 substituting cisplatin 120 mg/m2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients

    45 Survival advantage for carboplatin 500 mg/mg2 substituting cisplatin 120 mg/m2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients by Jelić, S., Radosavjelić, D., Elezar, E., Radulović, S., Ristović-Bizetić, Z.

    Published in Lung cancer (Amsterdam, Netherlands) (01-08-1997)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    45 Survival advantage for carboplatin 500 mg/mg 2 substituting cisplatin 120 mg/m 2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients

    45 Survival advantage for carboplatin 500 mg/mg 2 substituting cisplatin 120 mg/m 2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients by Jelić, S., Radosavjelić, D., Elezar, E., Radulović, S., Ristović-Bizetić, Z.

    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    1068 Cisplatin 120mg/m2 vs. carboplatin 500mg/m2 in combination with mitomycin c and vindesin; a randomized phase III study in 164 patients with stage IIIB and IV squamous-cell bronhogenic carcinoma

    1068 Cisplatin 120mg/m2 vs. carboplatin 500mg/m2 in combination with mitomycin c and vindesin; a randomized phase III study in 164 patients with stage IIIB and IV squamous-cell bronhogenic carcinoma by Jelić, S., Mitrović, L., Radosavljević, D., Elezar, E., Kovćin, V., Ristović, Z., Kovacević, S., Radulović, S.

    Published in European journal of cancer (1990) (01-11-1995)
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    1068 Cisplatin 120 mg/m 2 vs. carboplatin 500 mg/m 2 in combination with mitomycin c and vindesin; a randomized phase III study in 164 patients with stage IIIB and IV squamous-cell bronhogenic carcinoma

    1068 Cisplatin 120 mg/m 2 vs. carboplatin 500 mg/m 2 in combination with mitomycin c and vindesin; a randomized phase III study in 164 patients with stage IIIB and IV squamous-cell bronhogenic carcinoma by Jelić, S., Mitrović, L., Radosavljević, D., Elezar, E., Kovćin, V., Ristović, Z., Kovacević, S., Radulović, S.

    Published in European journal of cancer (1990) (1995)
    “…A randomized phase III study of Cisplatin vs. Carboplatin in 1:4 ration in patients with stage IIIb and IV squamous cell bronhogenic carcinoma, in combination…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: